{
"id": "ASSET-01",
"name": "DLL3 CAR-T in relapsed/refractory ES-SCLC",
"indication": "Extensive-stage small cell lung cancer (ES-SCLC), 3rd line+",
"seriousness": "Serious / life-threatening (median OS in 3L+ SCLC is a few months).",
"modality": "Autologous CAR-T cell therapy (regenerative medicine).",
"unmet_need": "No approved targeted therapy in 3L+ SCLC; remaining options are low-response palliative chemo. Clear unmet need vs available therapy.",
"available_therapy": "Topotecan / lurbinectedin / re-challenge chemo (ORR ~15-20%, not durable).",
"clinical_evidence": "Phase 1/2: confirmed ORR 55% vs ~15-20% for available chemo, with early durability (several responders >6 months). Human data in hand.",
"endpoint_type": "Surrogate (objective response rate) \u2014 OS not yet mature.",
"prevalence_us": 35000,
"pediatric": false,
"phase": "Phase 1/2"
}{
"programs": [
{
"id": "fast_track",
"name": "Fast Track",
"type": "Development designation",
"benefit": "Rolling review, more frequent FDA meetings/written communication, and eligibility for Accelerated Approval and Priority Review if criteria later met."
},
{
"id": "breakthrough",
"name": "Breakthrough Therapy (BTD)",
"type": "Development designation",
"benefit": "All Fast Track features PLUS intensive FDA guidance on efficient drug development starting as early as Phase 1, and organizational commitment (senior managers / cross-disciplinary review)."
},
{
"id": "accelerated_approval",
"name": "Accelerated Approval (AA)",
"type": "Approval pathway",
"benefit": "Approval can occur YEARS earlier, on the surrogate/intermediate endpoint, before overall-survival-type outcomes mature."
},
{
"id": "priority_review",
"name": "Priority Review",
"type": "Review designation",
"benefit": "Shortens the FDA REVIEW CLOCK to ~6 months (vs ~10 months standard)."
},
{
"id": "rmat",
"name": "Regenerative Medicine Advanced Therapy (RMAT)",
"type": "Development designation (regenerative medicine)",
"benefit": "All Breakthrough features (early intensive guidance) PLUS explicit eligibility for Accelerated Approval on surrogate/intermediate endpoints and flexible confirmatory-evidence options (e.g. real-world data, expanded registries)."
},
{
"id": "orphan",
"name": "Orphan Drug Designation",
"type": "Incentive designation",
"benefit": "7 years of orphan market exclusivity on approval, tax credits for clinical trials, and waiver of the (large) PDUFA application user fee."
},
{
"id": "rare_pediatric",
"name": "Rare Pediatric Disease (RPD) Designation + Priority Review Voucher",
"type": "Incentive designation (pediatric)",
"benefit": "On approval of the RPD product, the sponsor receives a TRANSFERABLE Priority Review Voucher (PRV) \u2014 sellable for ~$100M+ \u2014 redeemable to get Priority Review on any future application."
}
],
"ema_analogues": {
"prime": "PRIME (PRIority MEdicines) \u2014 EMA's enhanced-support scheme, loosely analogous to Breakthrough Therapy; for medicines targeting an unmet need with early evidence of major therapeutic advantage. Often paired with conditional marketing authorisation.",
"conditional_ma": "Conditional Marketing Authorisation \u2014 EMA analogue of Accelerated Approval; approval on less complete data for a serious/unmet-need condition, with an obligation to provide confirmatory comprehensive data post-authorisation.",
"ema_orphan": "EU Orphan Designation \u2014 analogue of US Orphan Drug; prevalence threshold \u2264 5 in 10,000 in the EU, grants 10 years market exclusivity."
},
"note": "Designations are NOT mutually exclusive; a strong strategy stacks several. Use get_program_criteria for the full qualifying criteria of each program."
}{
"id": "fast_track",
"name": "Fast Track",
"type": "Development designation",
"criteria": [
"Drug treats a SERIOUS or life-threatening condition.",
"Demonstrates potential to address an UNMET MEDICAL NEED, OR is a qualified infectious disease product.",
"Evidence bar is LOW: nonclinical data, or a plausible mechanistic / early clinical rationale, is enough \u2014 no efficacy data required."
],
"benefit": "Rolling review, more frequent FDA meetings/written communication, and eligibility for Accelerated Approval and Priority Review if criteria later met.",
"timing": "Any time, with the IND or after; FDA responds within 60 days.",
"gotcha": "Fast Track is about UNMET NEED + seriousness; it does NOT by itself speed the review clock \u2014 that is Priority Review."
}{
"id": "breakthrough",
"name": "Breakthrough Therapy (BTD)",
"type": "Development designation",
"criteria": [
"Drug treats a SERIOUS or life-threatening condition.",
"PRELIMINARY CLINICAL EVIDENCE (i.e. human data, not just nonclinical) indicates the drug may demonstrate SUBSTANTIAL IMPROVEMENT over AVAILABLE THERAPY ...",
"... on one or more CLINICALLY SIGNIFICANT ENDPOINT(s) (a durable, large effect \u2014 e.g. dramatic ORR/response vs a weak standard of care, or effect on a strong surrogate that represents a clear advance)."
],
"benefit": "All Fast Track features PLUS intensive FDA guidance on efficient drug development starting as early as Phase 1, and organizational commitment (senior managers / cross-disciplinary review).",
"timing": "Ideally by the end-of-Phase-2 meeting; FDA responds within 60 days.",
"gotcha": "The differentiator from Fast Track is the EVIDENCE TYPE and SIZE: BTD needs PRELIMINARY CLINICAL evidence of SUBSTANTIAL (not just any) improvement over AVAILABLE therapy. Nonclinical-only assets do not qualify."
}{
"id": "accelerated_approval",
"name": "Accelerated Approval (AA)",
"type": "Approval pathway",
"criteria": [
"Drug treats a SERIOUS or life-threatening condition.",
"Provides a MEANINGFUL ADVANTAGE over AVAILABLE THERAPY.",
"Shows an effect on a SURROGATE ENDPOINT, or an INTERMEDIATE CLINICAL endpoint, that is REASONABLY LIKELY TO PREDICT clinical benefit (e.g. ORR/tumor shrinkage as a stand-in for survival)."
],
"benefit": "Approval can occur YEARS earlier, on the surrogate/intermediate endpoint, before overall-survival-type outcomes mature.",
"timing": "An approval pathway, discussed pre-NDA/BLA; not a 60-day designation.",
"gotcha": "REQUIRES a confirmatory (Phase 4) trial to verify clinical benefit; the trial should generally be UNDERWAY at approval. If it fails, the drug can be withdrawn. Needs a SURROGATE/INTERMEDIATE endpoint \u2014 a fully mature OS readout is regular approval, not AA."
}{
"id": "priority_review",
"name": "Priority Review",
"type": "Review designation",
"criteria": [
"Application is for a drug that, if approved, would be a SIGNIFICANT IMPROVEMENT in the safety or effectiveness of treatment, diagnosis, or prevention of a SERIOUS condition (or qualifies via a Priority Review Voucher)."
],
"benefit": "Shortens the FDA REVIEW CLOCK to ~6 months (vs ~10 months standard).",
"timing": "Decided at the time the marketing application (NDA/BLA) is filed.",
"gotcha": "Acts only at REVIEW time on the FILED application \u2014 it does not affect the development program. A Rare Pediatric Disease PRV can also CONFER Priority Review on an unrelated product."
}{
"id": "rmat",
"name": "Regenerative Medicine Advanced Therapy (RMAT)",
"type": "Development designation (regenerative medicine)",
"criteria": [
"Drug is a REGENERATIVE MEDICINE THERAPY (cell therapy, therapeutic tissue engineering, human cell/tissue product, or qualifying combination \u2014 e.g. CAR-T, gene therapy).",
"Intended to treat, modify, reverse, or cure a SERIOUS or life-threatening condition.",
"PRELIMINARY CLINICAL EVIDENCE indicates the drug has potential to address UNMET MEDICAL NEEDS for that condition."
],
"benefit": "All Breakthrough features (early intensive guidance) PLUS explicit eligibility for Accelerated Approval on surrogate/intermediate endpoints and flexible confirmatory-evidence options (e.g. real-world data, expanded registries).",
"timing": "With the IND or after; FDA responds within 60 days.",
"gotcha": "It is the regenerative-medicine analogue of Breakthrough \u2014 ONLY for cell/gene/tissue products. A small molecule or naked mAb cannot get RMAT, even with great data."
}{
"id": "orphan",
"name": "Orphan Drug Designation",
"type": "Incentive designation",
"criteria": [
"Targets a RARE DISEASE/CONDITION: US prevalence < 200,000 patients (or a disease where development costs are not expected to be recovered from US sales).",
"Plausible scientific rationale that the drug treats the rare condition."
],
"benefit": "7 years of orphan market exclusivity on approval, tax credits for clinical trials, and waiver of the (large) PDUFA application user fee.",
"timing": "Any time before the marketing application is submitted.",
"gotcha": "Orphan status is about PREVALENCE/economics, NOT about how good the data is and NOT a faster review. It is independent of Fast Track / BTD / AA / Priority Review and stacks with them."
}For ASSET-01, the Phase 1/2 autologous DLL3 CAR-T therapy for relapsed/refractory extensive-stage small cell lung cancer (ES-SCLC), there is a clear regulatory strategy you could adopt with several potential FDA expedited programs.
Fast Track Designation:
- Qualifying Criteria: Treats a serious/life-threatening condition with potential to address an unmet medical need.
- Benefit: Enables rolling review, more frequent FDA communication, and eligibility for Accelerated Approval and Priority Review in the future.
- Timing: Can be requested any time, ideally early in development for ongoing feedback.
Breakthrough Therapy Designation (BTD):
- Qualifying Criteria: Must show preliminary clinical evidence indicating substantial improvement over existing therapies on a clinically significant endpoint.
- Benefit: Intensive guidance on development, similar to Fast Track but with a focus on demonstrating significant clinical improvement.
- Timing: Best sought ideally by the end-of-Phase-2 meeting.
Regenerative Medicine Advanced Therapy Designation (RMAT):
- Qualifying Criteria: Must be a regenerative medicine therapy, treat a serious/life-threatening condition, and show preliminary clinical evidence addressing an unmet need.
- Benefit: Similar to BTD with explicit eligibility for Accelerated Approval, also allows for more flexibility in confirmatory evidence.
- Timing: Request can be made with the IND or thereafter.
Accelerated Approval (AA):
- Qualifying Criteria: Must demonstrate a meaningful advantage over existing therapies, showing an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit.
- Benefit: Allows for earlier approval based on surrogate endpoints.
- Timing: Requires discussion pre-NDA/BLA; must already be underway at the time of application.
Priority Review:
- Qualifying Criteria: Application must represent a significant improvement in treatment for a serious condition.
- Benefit: Reduces FDA review timeframe from ~10 months to ~6 months.
- Timing: Determined when the NDA/BLA is filed.
Orphan Drug Designation:
- Qualifying Criteria: Must treat a rare condition, which ES-SCLC likely qualifies for (<200,000 patients).
- Benefit: Provides 7 years of market exclusivity, tax credits, and reduced user fees.
- Timing: Can apply anytime before the marketing application.
Using this strategy allows you to take advantage of multiple expedited designations, maximizing the chances of a successful regulatory submission and market entry for ASSET-01. The key is to ensure there is solid preliminary clinical evidence and careful management of the application processes for each designation.
For ASSET-01, the Phase 1/2 autologous DLL3 CAR-T therapy for relapsed/refractory extensive-stage small cell lung cancer (ES-SCLC), there is a clear regulatory strategy you could adopt with several potential FDA expedited programs.
Fast Track Designation:
- Qualifying Criteria: Treats a serious/life-threatening condition with potential to address an unmet medical need.
- Benefit: Enables rolling review, more frequent FDA communication, and eligibility for Accelerated Approval and Priority Review in the future.
- Timing: Can be requested any time, ideally early in development for ongoing feedback.
Breakthrough Therapy Designation (BTD):
- Qualifying Criteria: Must show preliminary clinical evidence indicating substantial improvement over existing therapies on a clinically significant endpoint.
- Benefit: Intensive guidance on development, similar to Fast Track but with a focus on demonstrating significant clinical improvement.
- Timing: Best sought ideally by the end-of-Phase-2 meeting.
Regenerative Medicine Advanced Therapy Designation (RMAT):
- Qualifying Criteria: Must be a regenerative medicine therapy, treat a serious/life-threatening condition, and show preliminary clinical evidence addressing an unmet need.
- Benefit: Similar to BTD with explicit eligibility for Accelerated Approval, also allows for more flexibility in confirmatory evidence.
- Timing: Request can be made with the IND or thereafter.
Accelerated Approval (AA):
- Qualifying Criteria: Must demonstrate a meaningful advantage over existing therapies, showing an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit.
- Benefit: Allows for earlier approval based on surrogate endpoints.
- Timing: Requires discussion pre-NDA/BLA; must already be underway at the time of application.
Priority Review:
- Qualifying Criteria: Application must represent a significant improvement in treatment for a serious condition.
- Benefit: Reduces FDA review timeframe from ~10 months to ~6 months.
- Timing: Determined when the NDA/BLA is filed.
Orphan Drug Designation:
- Qualifying Criteria: Must treat a rare condition, which ES-SCLC likely qualifies for (<200,000 patients).
- Benefit: Provides 7 years of market exclusivity, tax credits, and reduced user fees.
- Timing: Can apply anytime before the marketing application.
Using this strategy allows you to take advantage of multiple expedited designations, maximizing the chances of a successful regulatory submission and market entry for ASSET-01. The key is to ensure there is solid preliminary clinical evidence and careful management of the application processes for each designation.
Rule-based eligibility checklist for ASSET-01 (DLL3 CAR-T in relapsed/refractory ES-SCLC), applying each program's qualifying criteria to the scenario facts. A strong agent recovers the same QUALIFIES/DOESN'T calls with the right deciding criterion, handles the surrogate-vs-mature-endpoint and regenerative-vs-not distinctions, and notes the Accelerated-Approval confirmatory-trial obligation.
| FDA program | Eligibility | Deciding criterion |
|---|---|---|
| Fast Track | QUALIFIES | Serious condition addressing an unmet need; low evidence bar (nonclinical rationale suffices). |
| Breakthrough Therapy | QUALIFIES | Preliminary clinical evidence of substantial improvement over available therapy. |
| Accelerated Approval | QUALIFIES | Serious + meaningful advantage + effect on a surrogate/intermediate endpoint reasonably likely to predict benefit. REQUIRES a confirmatory trial. |
| Priority Review | QUALIFIES | Would be a significant improvement for a serious condition; request at NDA/BLA filing (also obtainable via a Rare-Pediatric PRV). |
| RMAT | QUALIFIES | Regenerative-medicine therapy for a serious condition with preliminary clinical evidence of potential to address unmet need. (Use INSTEAD of BTD for regen products; adds AA + flexible confirmatory evidence.) |
| Orphan Drug | QUALIFIES | US prevalence 35,000 < 200,000. |
| Rare Pediatric Disease PRV | DOESN'T | DOESN'T: not a primarily pediatric disease. |
| → Recommended pathway stack | RMAT; Accelerated Approval (with confirmatory trial underway); Orphan Drug; Priority Review (at filing) | Designations are not mutually exclusive; sequence them across development (designation → development support → approval pathway → review). |